NXI Therapeutics

About:

NXI Therapeutics develops next-gen immunosuppressive drugs for autoimmune diseases and organ transplantation.

Website: https://nxitherapeutics.com

Top Investors: Venture Kick, Kickfund, University of Basel, Gebert Rüf Stiftung, BaseLaunch

Description:

NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical and early clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives.

Total Funding Amount:

3.5M CHF

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2021-01-01

Contact Email:

contact(AT)nxitherapeutics.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2024-06-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai